1,721
Participants
Start Date
July 25, 2020
Primary Completion Date
March 31, 2021
Study Completion Date
June 16, 2024
Questionnaire including validated tools such as Patient Health Questionnaire (PHQ-9), the 7-item Generalised Anxiety Disorder (GAD- 7), the 7-item insomnia severity index
The electronic survey for phase 1 detailing questions regarding affective symptoms, behaviour and ongoing concerns will be sent and implied consent assumed from responders. A proportion of these patients who give consent to be repeatedly contacted throughout the study period will be recruited into phase 2 of the study at 6 weeks and 4 months
Questionnaire, same tools as before, with inclusion of PCL5 questionnaire too.
Follow-up electronic surveys including questions regarding affective symptoms, behavioural changes and mental well-being will be sent at 6-weeks and 4-months following the initial survey. This will be sent to participants from Groups 1-3 that provided consent to receive these follow-up questionnaires.
Informed consent
Participants will need to give their consent to participate to the survey after reading PIS
Ajay K Gupta, London
Queen Mary University of London
OTHER